EGCG blocks TGFβ1-induced CCN2 by suppressing JNK and p38 in buccal fibroblasts

Clinical Oral Investigations

Volumn 17, Issue 2, 2013, Pages 455-461

  Chang, Jenny Zwei Chieng ^a   Yang, Wan Hsien ^a   Deng, Yi Ting ^a   Chen, Hsin Ming ^a   Kuo, Mark Yen Ping ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Connective tissue growth factor; CTGF CCN2; EGCG; Oral submucous fibrosis; TGF 1; Transforming growth factor

Indexed keywords

EID: 84874349261     PISSN: 14326981     EISSN: 14363771     Source Type: Journal    
DOI: 10.1007/s00784-012-0713-5     Document Type: Article

References (30)

1. Rajalalitha P, Vali S (2005) Molecular pathogenesis of oral submucous fibrosis-a collagen metabolic disorder. J Oral Pathol Med 34: 321-328.
2. Angadi PV, Rao SS (2011) Areca nut in pathogenesis of oral submucous fibrosis: revisited. Oral Maxillofac Surg 15: 1-9.
3. Moutasim KA, Jenei V, Sapienza K, Marsh D, Weinreb PH, Violette SM et al (2011) Betel-derived alkaloid up-regulates keratinocyte alphavbeta6 integrin expression and promotes oral submucous fibrosis. J Pathol 223: 366-377.
4. Tilakaratne WM, Klinikowski MF, Saku T, Peters TJ, Warnakulasuriya S (2006) Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol 42: 561-568.
5. Huang CH, Shieh TY (1999) Immunohistochemical expression of transforming growth factor beta in oral submucous fibrosis. J Acad Formos Stomatol 15: 227-239.
6. Tian M, Neil JR, Schiemann WP (2011) Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 23: 951-962.
7. Wrzesinski SH, Wan YY, Flavell RA (2007) Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 13: 5262-5270.
8. Lau LF, Lam SC (1999) The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 248: 44-57.
9. Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18: 816-827.
10. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A (2001) CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 276: 10594-10601.
11. Leask A, Sa S, Holmes A, Shiwen X, Black CM, Abraham DJ (2001) The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol 54: 180-183.
12. Haydont V, Riser BL, Aigueperse J, Vozenin-Brotons MC (2008) Specific signals involved in the long-term maintenance of radiation-induced fibrogenic differentiation: a role for CCN2 and low concentration of TGF-beta1. Am J Physiol Cell Physiol 294: C1332-C1341.
13. Deng YT, Chen HM, Cheng SJ, Chiang CP, Kuo MY (2009) Arecoline-stimulated connective tissue growth factor production in human buccal mucosal fibroblasts: modulation by curcumin. Oral Oncol 45: e99-e105.
14. Black SA Jr, Palamakumbura AH, Stan M, Trackman PC (2007) Tissue-specific mechanisms for CCN2/CTGF persistence in fibrotic gingiva: interactions between cAMP and MAPK signaling pathways, and prostaglandin E2-EP3 receptor mediated activation of the c-JUN N-terminal kinase. J Biol Chem 282: 15416-15429.
15. Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM et al (2002) Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J 16: 1949-1951.
16. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X et al (1999) Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J 13: 1774-1786.
17. Chang JZ, Yang W, Deng Y, Chen H, Kuo MY (2011) Thrombin-stimulated connective tissue growth factor (CTGF/CCN2) production in human buccal mucosal fibroblasts: inhibition by epigallocatechin-3-gallate. Head Neck. doi: 10. 1002/hed. 21863.
18. Tsai CH, Chou MY, Chang YC (2003) The up-regulation of cyclooxygenase-2 expression in human buccal mucosal fibroblasts by arecoline: a possible role in the pathogenesis of oral submucous fibrosis. J Oral Pathol Med 32: 146-153.
19. Prime SS, Pring M, Davies M, Paterson IC (2004) TGF-beta signal transduction in oro-facial health and non-malignant disease (part I). Crit Rev Oral Biol Med 15: 324-336.
20. Massague J (1998) TGF-beta signal transduction. Annu Rev Biochem 67: 753-791.
21. Shi-wen X, Stanton LA, Kennedy L, Pala D, Chen Y, Howat SL et al (2006) CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts. J Biol Chem 281: 10715-10726.
22. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM et al (2007) Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56: 323-333.
23. Kang JS, Liu C, Derynck R (2009) New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol 19: 385-394.
24. Flanders KC (2004) Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 85: 47-64.
25. Thompson K, Hamilton DW, Leask A (2010) ALK5 inhibition blocks TGF-beta-induced CCN2 expression in gingival fibroblasts. J Dent Res 89: 1450-1454.
26. Cicha I, Goppelt-Struebe M (2009) Connective tissue growth factor: context-dependent functions and mechanisms of regulation. Biofactors 35: 200-208.
27. Sriram N, Kalayarasan S, Sudhandiran G (2009) Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates, lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis. Chem Biol Interact 180: 271-280.
28. Tipoe GL, Leung TM, Liong EC, Lau TY, Fung ML, Nanji AA (2010) Epigallocatechin-3-gallate (EGCG) reduces liver inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-induced liver injury in mice. Toxicology 273: 45-52.
29. Hao J, Kim CH, Ha TS, Ahn HY (2007) Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Sci 8: 121-129.
30. Dooley A, Shi-Wen X, Aden N, Tranah T, Desai N, Denton CP et al (2010) Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Rheumatology (Oxford) 49: 2024-2036.